Journal of the Neurological Sciences
Volume 206, Issue 2 , Pages 123-130 , 15 February 2003

The role of intravenous immunoglobulin in the treatment of multiple sclerosis

References 

  1. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain–Barre syndrome. Dutch Guillain–Barre Study Group. N. Engl. J. Med. 1992;326:1123–1129
  2. van den Berg LH, Franssen H, Van Doorn PA, Wokke JH. Intravenous immunoglobulin treatment in lower motor neuron disease associated with highly raised anti-GM1 antibodies. J. Neurol. Neurosurg. Psychiatry. 1997;63:674–677
  3. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, et al.  A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol. 1994;36:838–845
  4. Hafler DA, Brod SA, Weiner HL. Immunoregulation in multiple sclerosis. Res. Immunol. 1989;140:233–239
  5. Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. 1996;6:259–274
  6. Storch M, Lassmann H. Pathology and pathogenesis of demyelinating diseases. Curr. Opin. Neurol. 1997;10:186–192
  7. Bruck W, Bitsch A, Kolenda H, Bruck Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann. Neurol. 1997;42:783–793
  8. Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann. Neurol. 1998;43:465–471
  9. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000;47:707–717
  10. Dalakas MC. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology. 1998;51(6 Suppl. 5):S2–S8
  11. Dalakas MC. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve. 1999;22:1479–1497
  12. Kaveri SV, Mouthon L, Kazatchkine MD. Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases. J. Neurol. Neurosurg. Psychiatry. 1994;57:6–8 [Supplement]
  13. Kazatchkine MD, Bellon B, Kaveri SV. Mechanisms of action of intravenous immunoglobulin (IVIG). Mult. Scler. 2000;6(Suppl. 2):S24–S26
  14. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 2001;345:747–755
  15. Andersson JP, Andersson UG. Human intravenous immunoglobulin modulates monokine production in vitro. Immunology. 1990;71:372–376
  16. Ross C, Svenson M, Nielsen H, Lundsgaard C, Hansen MB, Bendtzen K. Increased in vivo antibody activity against interferon alpha, interleukin-1alpha, and interleukin-6 after high-dose Ig therapy. Blood. 1997;90:2376–2380
  17. Frank MM, Basta M, Fries LF. The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin. Immunol. Immunopathol. 1992;62:S82–S86
  18. Bieber A, Asakura K, Warrington A, Kaveri SV, Rodriguez M. Antibody-mediated remyelination: relevance to multiple sclerosis. Mult. Scler. 2000;6(Suppl. 2):S1–S5
  19. Lucchinetti CF, Noseworthy JH, Rodriguez M. Promotion of endogenous remyelination in multiple sclerosis. Mult. Scler. 1997;3:71–75
  20. Miller DJ, Asakura K, Rodriguez M. Experimental strategies to promote central nervous system remyelination in multiple sclerosis: insights gained from the Theiler's virus model system. J. Neurosci. Res. 1995;41:291–296
  21. Rodriguez M, Lennon VA, Benveniste EN, Merrill JE. Remyelination by oligodendrocytes stimulated by antiserum to spinal cord. J. Neuropathol. Exp. Neurol. 1987;46:84–95
  22. Rodriguez M, Lennon VA. Immunoglobulins promote remyelination in the central nervous system. Ann. Neurol. 1990;27:12–17
  23. Rodriguez M, Miller DJ, Lennon VA. Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology. 1996;46:538–545
  24. van Engelen BG, Miller DJ, Pavelko KD, Hommes OR, Rodriguez M. Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 1994;57:65–68 [Supplement]
  25. Wurster U, Haas J. Passage of intravenous immunoglobulin and interaction with the CNS. J. Neurol. Neurosurg. Psychiatry. 1994;57:21–25 [Supplement]
  26. Sorensen PS, Wanscher B, Jensen CV, Schreiber K, Blinkenberg M, Ravnborg M, et al.  Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology. 1998;50:1273–1281
  27. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al.  Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000;6:916–919
  28. Sorensen PS. Intravenous immunoglobulin G therapy: effects of acute and chronic treatment in multiple sclerosis. Mult. Scler. 1996;1:349–352
  29. Rothfelder U, Neu I, Pelka R. Therapy of multiple sclerosis with immunoglobulin G. MMW, Munch Med. Wochenschr. 1982;124:74–78
  30. Schuller E, Govaerts A. First results of immunotherapy with immunoglobulin G in multiple sclerosis patients. Eur. Neurol. 1983;22:205–212
  31. Schuller E, Lambin P, Deloche G. Long-term treatment of multiple sclerosis with IgG immunotherapy. Pathol. Biol. (Paris). 1996;44:710–715
  32. Cook SD, Troiano R, Rohowsky Kochan C, Jotkowitz A, Bielory L, Mehta PD, et al.  Intravenous gamma globulin in progressive MS. Acta Neurol. Scand. 1992;86:171–175
  33. Achiron A, Pras E, Gilad R, Ziv I, Mandel M, Gordon CR, et al.  Open controlled therapeutic trial of intravenous immune globulin in relapsing–remitting multiple sclerosis. Arch. Neurol. 1992;49:1233–1236
  34. Achiron A, Cohen IR, Lider O, Melamed E. Intravenous immunoglobulin treatment in multiple sclerosis. Isr. J. Med. Sci. 1995;31:7–9
  35. Francis GS, Freedman MS, Antel JP. Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: a clinical and MRI based study. Mult. Scler. 1997;3:370–376
  36. Kalanie H, Tabatabai SS. Combined immunoglobulin and azathioprine in multiple sclerosis. Eur. Neurol. 1998;39:178–181
  37. Fazekas F, Deisenhammer F, Strasser Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing–remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet. 1997;349:589–593
  38. Strasser-Fuchs S, Fazekas F, Deisenhammer F, Nahler G, Mamoli B. The Austrian Immunoglobulin in MS (AIMS) study: final analysis. Mult. Scler. 2000;6(Suppl. 2):S9–S13
  39. Poser CM. Intravenous immunoglobulin for multiple sclerosis. Lancet. 1997;349(9059):1177–1178
  40. Achiron A, Gabbay U, Gilad R, Hassin BS, Barak Y, Gornish M, et al.  Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology. 1998;50:398–402
  41. Sorensen PS, Wanscher B, Schreiber K, Blinkenberg M, Jensen CV, Ravnborg M. A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: preliminary results. Mult. Scler. 1997;3:145–148
  42. Lewanska M, Zajdel MS, Selmaj K. Low dose of intravenous immunoglobulins is equally effective in multiple sclerosis as high dose. Clinical and MRI assessment. Eur. J. Neurol. 2002;9:565–572
  43. Achiron A, Rotstein Z, Noy S, Mashiach S, Dulitzky M, Achiron R. Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study. J. Neurol. 1996;243:25–28
  44. Haas J. High dose IVIG in the post partum period for prevention of exacerbations in MS. Mult. Scler. 2000;6(Suppl. 2):S18–S20
  45. Soukop W, Tschabitscher H. Gamma globulin therapy in multiple sclerosis. Theoretical considerations and initial clinical experiences with 7S immunoglobulins in MS therapy. Wien Med. Wochenschr. 1986;136:477–480
  46. Sahlas DJ, Miller SP, Guerin M, Veilleux M, Francis G. Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin. Neurology. 2000;54(6):1370–1372
  47. Nos C, Comabella M, Tintore M, Rio J, Codina A, Montalban X. Rovira A: high dose intravenous immunoglobulin does not improve abnormalities in the blood–brain barrier during acute relapse of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 1996;61:418
  48. van Engelen BG, Hommes OR, Pinckers A, Cruysberg JR, Barkhof F, Rodriguez M. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Ann. Neurol. 1992;32:834–835
  49. Noseworthy JH, O'Brien PC, Petterson TM, Weis J, Stevens L, Peterson WK, et al.  A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology. 2001;56:1514–1522
  50. Noseworthy JH, O'Brien PC, Weinshenker BG, Weis JA, Petterson TM, Erickson BJ, et al.  IV immunoglobulin does not reverse established weakness in MS. Neurology. 2000;55:1135–1143
  51. Stangel M, Boegner F, Klatt CH, Hofmeister C, Seyfert S. Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 2000;68:89–92
  52. Sorensen PS, Pozilli C, Kölmel HW, Fernandez O, Blumhardt L, O'Connor P, et al.  the ESIMS Study Group   European study on intravenous immunoglobulin in multiple sclerosis (ESIMS): design of the study and preliminary results. J. Neurol. Sci. 2003; [in press]
  53. Goodin DS, Frohman EM, Garmany GP, et al.  Disease modifyng therapies in multiple sclerosis. Neurology. 2002;58:169–178
  54. The IFNB Multiple Sclerosis Study Group . Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655–661
  55. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group . Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 1995;45:1277–1285
  56. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al.  Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 1996;39:285–294
  57. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group . Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352:1498–1504
  58. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing–remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45:1268–1276
  59. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol. 2001;49:290–297
  60. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group . Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology. 2001;56:1496–1504
  61. Li DK, Zhao GJ, Paty DW. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology. 2001;56:1505–1513

PII: S0022-510X(02)00343-X

Journal of the Neurological Sciences
Volume 206, Issue 2 , Pages 123-130 , 15 February 2003

Article Tools